drugset / Trial / NCT00752323

Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma

NCT00752323

Phase 2 Completed 73 enrolled Andrew Sloan, MD
RandomizedParallel-groupSingle-blindDiagnostic

Summary

RATIONALE: Imaging procedures that use aminolevulinic acid (ALA) may help find and diagnose residual tumor in participants with grade IV malignant astrocytoma who are undergoing surgery to remove the tumor. PURPOSE: Our primary long-term goal is to improve the completeness of surgical resection of malignant brain tumor through image- guided fluorescence localization. We hypothesize that the use of qualitative fluorescence imaging and point PpIX concentration quantification will enable more complete tumor resection than normal direct (i.e., white light) visualization, and thereby improve participant survival.

Timeline

Start
2009-12-08
Primary completion
2018-09-15
Completion
2018-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent 10 mg/kg Oral
Subject Aminolevulinic Acid Diagnostic / imaging agent 20 mg/kg Oral